Trial Profile
Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 22 Apr 2024
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Durvalumab (Primary) ; Paclitaxel (Primary)
- Indications Advanced breast cancer; Early breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- 14 Nov 2023 Planned initiation date (estimated date of first participant enrollment) changed from 30 Oct 2023 to 26 Jul 2024.
- 14 Nov 2023 Status changed from not yet recruiting to recruiting.
- 31 Oct 2023 According to an Agendia media release, company is collaborating with National Cancer Institute (NCI), part of the National institutes of Health and SWOG Cancer Research Network, funded by NCI, for a new clinical trial that will test the effectiveness of neoadjuvant immunotherapy for high-risk HR+ breast cancer patients.